Literature DB >> 837952

Allopurinol in the recurrence prevention of calcium oxalate lithiasis.

G Brien, C Bick.   

Abstract

Since 1973 we have used allopurinol in the prevention and aftercare of recurrent urolithiasis. We give indications for the administration of allopurinol for patients with chronically recurring calcium oxalate lithiasis. Special attention is given to the urinary stone analysis as well as to metabolic disorders as for example hyperuricaemia, hyperuricuria or idiopathic hypercalciuria. In 15 patients with calcium oxalate lithiasis the stone/patient/year ratio could be decreased to 38%. In 19 patients with uric acid/calcium oxalate calculi or alternating stone formations from uric acid and calcium oxalate we succeeded in decreasing this ratio from 1.72 to 0.47 or 27%.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837952     DOI: 10.1159/000472051

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

1.  Effects of sodium urate and uric acid crystals on the crystallization of calcium oxalate.

Authors:  H G Tiselius
Journal:  Urol Res       Date:  1984

2.  Urinary excretion of urate in patients with calcium oxalate stone disease.

Authors:  H G Tiselius; L Larsson
Journal:  Urol Res       Date:  1983

3.  Dose-response relationship between higher serum calcium level and higher prevalence of hyperuricemia: A cross-sectional study.

Authors:  Zhichen Liu; Xiang Ding; Jing Wu; Hongyi He; Ziying Wu; Dongxing Xie; Zidan Yang; Yilun Wang; Jian Tian
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.